A clinical trial of progressive progression is carried out directly in the brain by an experimental treatment, it is expected that Parkinson's disease will be recovered from the affected cells. According to the study, the Glial Cell Line Derived Neurotrophic Factor (GDNF) factor in the natural factors that improve the levels of Parkinson's disease regenerate the dopamine-brain cells and to reverse this condition, the existing treatment can not be performed. Thanks to the results of the third arm of the tests, they are studying a wide open label Parkinson's disease.
Three billion pounds after GDNF, he financed the United Kingdom of Parkinson in The Cure Parkinson's Trust and North Bristol NHS Trust.
Six patients participated in the initial pilot study to evaluate the safety of treatment. The other 35 people participated in a double-blind double-blind session, of which half were randomly assigned to the infusions of the GDNF and half infusions. At the end of the nine months after the GDNF or the placebo, an open label extension was performed, the effects of monitoring and safety of the GDNF were analyzed for 40 weeks of GDNF (80 weeks total), and the effects of 40 decades of GDNF open label with previous pre-40 weeks. In the study of parents (41 patients with courage and treatment in patients with previous GDNFs and placebo patients), they enrolled and opened the label to open the label.
A specially designed delivery system was introduced by robot-assisted neurosurgery. The delivery system can give you a high infusion rate that is transmitted every four weeks and is called Advanced Convex Enhanced Drug (CED). Four tubes were carefully monitored in each patient's brain, which could directly affect areas affected by GDNF by means of transcripts crossed by the ear behind the ear. After several years of implantation, the trial team manages more than 1000 brain infusions every four months, every 18 months to learn the participants. 99.1% of the UK's recruits (99.1%) have potentially shown that this new administration of the brain infusions is clinically feasible and tolerant.
After nine months, there has been no change in the PET search for those with placebo, the GDNF group has shown a 100% improvement in the key area of the brain affected conditions, recovering from recovery and recovering the affected cells from the brain.
"The brain's search for a spatial and relative magnitude to improve treatment before treatment with Parkinson's growth factors is beyond that," explained Dr. Alan L. Whone, FRCP, Translational Health Sciences, Bristol Medical School, Bristol University, and Neurology and Musuloskeletal Science Division, North Bristol NHS Trust, Bristol, United Kingdom. "This is one of the most credible proofs that continue to dry and recover the dopamine brain cells that gradually destroy Parkinson's."
After 18 months, when all participants received GDNF, both groups showed moderate and large symptoms to improve their symptoms before they started the study and the GDNF was safe for a long time. However, without a significant difference between the groups (after the GDNF and GDNF follow-up study, placebo was observed among the second and second class clinics).
In the case of biological changes that are left behind the biological changes seen in PET studies, or in the event of a longer period of repetitive exposure to development, they can not be permanently answered depending on the results of the exams. However, the integration of two research results is as follows:
- For people over 18 months of age, every four months of infusions can be taken via a cruise port.
- This treatment regimen and the new drug administration method are well tolerated.
- More detailed GDNF analysis in the use of large-scale and higher doses should be defined definitively, as the GDNF must play a role in future Parkinson's treatment as a measurable.
Steven Gill, MB, MS (Lond.), FRCS, lead neuro-surgeons and CED device designer, Neurology and Musculoskeletal Sciences Division, North Bristol NHS Trust, Bristol and Renishaw plc, New Mills, Wotton-under-Edge, Gloucestershire, United Kingdom, "This process has been proven safely and again and again in the brain of the patients can be infused directly over the course of months or years. It is a significant possibility for developing neurological illnesses, such as Parkinson's disease, because most drugs can not be considered a natural protection against bloodstream."
"It is essential to continue exploring this research treatment – the GDNF continues to be a potential to improve the lives of people in Parkinson," commented Dr. Whone
I think that this approach may be the first neuro-resistance to people in Parkinson's life, which is, of course, a very exciting prospect, "added Dr. Gill.
Materials provided by materials IOS Press. Note: Content can be edited by style and length.